BioWorld Asia

April 16, 2003

Celltech Poised To Acquire OGS After Other Parties Drop Interest

LONDON - Oxford GlycoSciences plc succumbed to the hostile bid from Celltech plc that will lead to the breakup of the business, after failing to attract any better offers. (BioWorld International) Read More

Oxxon Completes £15M Round To Fund Therapeutic Vaccines

Engineered Lymphocytes Show Promise In Metastatic Cancer

Karo Bio Plans To Net SEK120M From Discounted Rights Issue

Affitech, NatImmune Team Up In Colon Cancer Collaboration

Entomed, Achillion Enter Deal For Antiviral Drug Discovery

European Parliament Moves For Strict Cell, Tissue Rules

EU Consumer Commissioner Favors Progress In Biotech

IDM Acquires Cancer Assets For Stock In Deal With Jenner

Proteome Sciences, IDEXX Enter Deal To Develop BSE Diagnostic

MedPharma Looking To Go Public To Fund Sexual Dysfunction Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...